SPTBN2 promotes an immunosuppressive tumor microenvironment and cross-resistance to anti-cancer therapies
Quoc Thang Bui(University of Pennsylvania), Serge Y. Fuchs(University of Pennsylvania), Ágnes Holczbauer(University of Pennsylvania), Wei Guo(California University of Pennsylvania), Mayura Dhamdhere(University of Pennsylvania), Luca Paruzzo(Hospital of the University of Pennsylvania), Puneeth Guruprasad(Parker Institute for Cancer Immunotherapy), Ben Z. Stanger(Cancer Research Institute), Vladimir S. Spiegelman(Pennsylvania State University), Hallgeir Rui(Thomas Jefferson University), Matthew J. Atherton(University of Pennsylvania), Will Bailis(Children's Hospital of Philadelphia), Michael Scaglione(University of Pennsylvania), Raghavendra Basavaraja(Hebrew University of Jerusalem), Constantinos Koumenis(University of Pennsylvania), Marco Ruella(Parker Institute for Cancer Immunotherapy), Daniel P. Beiting(University of Pennsylvania), Yu Sun(University of Pennsylvania), J. Alan Diehl(Case Western Reserve University), Yi Fan(University of Pennsylvania), Lynn Spruce(Children's Hospital of Philadelphia), Kai Tan(University of Pennsylvania), Yingying Tang(University of Pennsylvania), Crystal S. Conn(University of Pennsylvania), Alice Wang(University of Pennsylvania), Erik Nash(Children's Hospital of Philadelphia)
Cited by 0
Related Papers
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
|Nature Cell Biology|2015|2.7k
Guidelines and definitions for research on epithelial–mesenchymal transition
|Nature Reviews Molecular Cell Biology|2020|2.3k
The Death Domain Kinase RIP Mediates the TNF-Induced NF-κB Signal
|Immunity|1998|1.1k
RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death
|Cell|1995|975
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554